In clinical trials , about 2% of participants reported gastroesophageal reflux disease (GERD)at lower doses of Ozempic
But as more studies and analysis of patient records occur, its clear these severe side effects are becoming more and more consistent for patients taking GLP-1 medications, including Zepbound and Wegovy
While GEP-44 remains in preclinical development, these early findings position SureNano Science within a highly strategic segment of the obesity treatment landscape
These data demonstrate that the effects of semaglutide-induced weight loss are not restricted to individuals with very high BMI but apply across the entire spectrum of obesity
Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE et al (2019) Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: a post hoc analysis of the LEADER and SUSTAIN 6 clinical trials